A review of the new antifungals: posaconazole, micafungin, and anidulafungin.
This column reviews 3 new systemic antifungal agents (posaconazole, micafungin, and anidulafungin) from the standpoint of dermatology. Posaconazole, approved to treat invasive Aspergillus and Candida infections, is available in an oral suspension and resembles fluconazole, but seems to have a broader spectrum of activity. Posaconazole is effective against yeasts and molds and could be effective in treating rare fungal infections involving Zygomycetes, Mucor necrotizing fasciitis, rhinocerebral mucormycosis, some Fusarium species, Penicillium, Histoplasma, Blastomyces, Coccidioides, Paracoccidioides, and sporotrichosis, chromoblastomycosis, mycetoma, and phaeohyphomycosis, including Scedosporium apiospermum and Exophiala, Alternaria, and Bipolaris species. Posaconazole may abate onychomycosis and dermatophytes, but clinical trial data is lacking. Micafungin and anidulafungin are echinocandins like caspofungin and are useful salvage therapy for invasive aspergillosis and candidiasis. The exciting new agents have extended the armamentarium against antifungal pathogens, but have yet to find their place in the dermatologic practice.
Scheinfeld
Noah
N
Department of Dermatology, St. Luke's-Roosevelt Hospital Center, New York, New York 10025, USA.
D000284:Administration, Oral; D000077612:Anidulafungin; D000935:Antifungal Agents / Q000008:administration & dosage*; D003881:Dermatomycoses / Q000188:drug therapy* / Q000382:microbiology; D054714:Echinocandins / Q000008:administration & dosage*; D006801:Humans; D007262:Infusions, Intravenous; D055666:Lipopeptides; D008074:Lipoproteins / Q000008:administration & dosage*; D000077551:Micafungin; D014230:Triazoles / Q000008:administration & dosage*
D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D008074:Lipoproteins; D014230:Triazoles; C101425:posaconazole; D000077612:Anidulafungin; D000077551:Micafungin